Core Viewpoint - Amwell, a leading provider of a SaaS-based software platform for technology-enabled healthcare, announced its financial results for Q4 and the full year of 2025, highlighting its growth and operational scale in the healthcare sector [1]. Financial Results - The financial results for the fourth quarter and full year ended December 31, 2025, are available for review, indicating the company's performance and growth metrics [1]. Company Overview - Amwell provides a comprehensive, technology-enabled care platform for payers and health systems, enhancing patient access to convenient, affordable, and effective care [3]. - The platform includes software and services that support various clinical programs, allowing for unified and personalized patient experiences across the care continuum [3]. - Amwell has been operational for nearly two decades, serving major healthcare organizations in the U.S. and globally, demonstrating its capability to deliver dependable outcomes at scale [3].

Core Insights - Digital healthcare platforms are expanding in consumer wellness and precision medicine, with Hims & Hers Health, Inc. (HIMS) focusing on consumer-first services and Tempus AI, Inc. (TEM) leveraging AI for precision medicine [1][2] Company Overview - HIMS operates a subscription-based platform providing personalized treatments through telehealth and pharmacy services, while TEM utilizes AI on clinical and molecular data for healthcare providers [1][2] - HIMS is expanding into lab testing and diagnostics, enhancing its service offerings in weight management, hormone health, and preventive care [6][7] - TEM is building a multimodal dataset for diagnostics and clinical decision-making, enhancing its value to healthcare providers and researchers [10][12] Stock Performance & Valuation - HIMS has underperformed with a 40.4% decline over the past three months, while TEM has decreased by 24.9% [3] - HIMS is trading at a forward price-to-sales (P/S) ratio of 2.35X, in line with the Medical sector average, whereas TEM's P/S ratio is 7.35X, above the sector average [4] Growth Drivers for Hims & Hers - HIMS is broadening its portfolio, which is expected to increase its addressable market and customer engagement [7] - The company's vertically integrated, data-driven care model enhances personalized treatment plans and quality control [8] - Global expansion and strategic capital deployment are expected to sustain long-term growth and recurring revenue [9] Growth Drivers for Tempus AI - TEM's data advantage from genomic testing and clinical data collection supports its diagnostic offerings and licensing business [10] - Increased adoption of TEM's diagnostic tools reflects integration into clinical workflows, bolstered by regulatory clearances [11] - AI-driven product expansion positions TEM as a technology partner, enhancing its long-term growth narrative [12] Earnings Projections - The Zacks Consensus Estimate for HIMS suggests a 16.8% improvement in EPS for 2026 compared to 2025 [15] - The Zacks Consensus Estimate for TEM indicates a 71.6% improvement in loss per share for 2026 compared to 2025 [18] Price Targets - Analysts project an average price target of $43.85 for HIMS, indicating a potential increase of 51.8% from the last close [20] - For TEM, the average price target is $87.92, suggesting a 34.6% increase from the last close [21] Investment Perspective - HIMS is viewed as a more favorable investment due to its consumer-focused model and expanding service offerings, despite being rated as a Zacks Rank 4 (Sell) [22] - TEM, also rated as Zacks Rank 4, has a compelling long-term growth narrative but trades at a higher valuation, indicating less margin for error [25][26]

Core Viewpoint - Amwell is set to report its second quarter 2025 operating results on August 5, 2025, after market hours, followed by a live conference call to discuss the results and provide a business update [1]. Company Overview - Amwell provides a comprehensive SaaS-based software platform aimed at technology-enabled healthcare, facilitating better access to convenient, affordable, and effective care for patients [3]. - The platform integrates software and services that support various clinical programs, allowing for personalized access to diverse healthcare services [3]. - Amwell has been operational for nearly two decades, serving major healthcare organizations in the U.S. and globally, and is capable of delivering care to millions of patients [3]. Upcoming Events - Company executives will participate in investor conferences, including one-on-one meetings at the Wells Fargo Healthcare Conference on September 4 and the Morgan Stanley Global Healthcare Conference on September 9 [4].

Company Overview - Amwell is a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, offering a unified care platform for payers and health systems [1] - The platform enhances patient access to convenient, affordable, and effective care, integrating various clinical programs [1] - Amwell has been operational for almost two decades, serving major healthcare organizations in the U.S. and globally [1] Upcoming Events - Mark Hirschhorn, CFO and COO of Amwell, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference on May 8 [4] - On June 24, Hirschhorn will also participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City [4]